Recommended Topic Related To:

Pradaxa

"Feb. 10, 2011 (Los Angeles) -- The experimental anti-clotting drug apixaban beat aspirin at preventing dangerous blood clots or strokes in people with the abnormal heart rhythm atrial fibrillation, according to final results of the so-called AVER"...

Pradaxa

Side Effects
Interactions

SIDE EFFECTS

The most serious adverse reactions reported with PRADAXA were related to bleeding [see WARNINGS AND PRECAUTIONS].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Reduction of Risk of Stroke and Systemic Embolism in Non-valvular Atrial Fibrillation

The RE-LY (Randomized Evaluation of Long-term Anticoagulant Therapy) study provided safety information on the use of two doses of PRADAXA and warfarin [see Clinical Studies]. The numbers of patients and their exposures are described in Table 1. Limited information is presented on the 110 mg dosing arm because this dose is not approved.

Table 1 : Summary of Treatment Exposure in RE-LY

  PRADAXA 110 mg twice daily PRADAXA 150 mg twice daily Warfarin
Total number treated 5983 6059 5998
Exposure      
   > 12 months 4936 4939 5193
   > 24 months 2387 2405 2470
Mean exposure (months) 20.5 20.3 21.3
Total patient-years 10,242 10,261 10,659

Drug Discontinuation in RE-LY

The rates of adverse reactions leading to treatment discontinuation were 21% for PRADAXA 150 mg and 16% for warfarin. The most frequent adverse reactions leading to discontinuation of PRADAXA were bleeding and gastrointestinal events (i.e., dyspepsia, nausea, upper abdominal pain, gastrointestinal hemorrhage, and diarrhea).

Bleeding

[see WARNINGS AND PRECAUTIONS]

Table 2 shows the number of patients experiencing serious bleeding during the treatment period in the RE-LY study, with the bleeding rate per 100 patient-years (%). Major bleeds fulfilled one or more of the following criteria: bleeding associated with a reduction in hemoglobin of at least 2 grams per deciliter or leading to a transfusion of at least 2 units of blood, or symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding). A life-threatening bleed met one or more of the following criteria: fatal, symptomatic intracranial bleed, reduction in hemoglobin of at least 5 grams per deciliter, transfusion of at least 4 units of blood, associated with hypotension requiring the use of intravenous inotropic agents, or necessitating surgical intervention. Intracranial hemorrhage included intracerebral (hemorrhagic stroke), subarachnoid, and subdural bleeds.

Table 2 : Bleeding Events* (per 100 Patient-Years)

  PRADAXA 150 mg twice daily
N (%)
Warfarin
N (%)
Hazard Ratio (95% CI**)
Randomized patients 6076 6022  
Patient-years 12,033 11,794  
  Intracranial hemorrhage 38 (0.3) 90 (0.8) 0.41 (0.28, 0.60)
  Life-threatening bleed 179 (1.5) 218 (1.9) 0.80 (0.66, 0.98)
  Major bleed 399 (3.3) 421 (3.6) 0.93 (0.81, 1.07)
  Any bleed 1993 (16.6) 2166 (18.4) 0.91 (0.85, 0.96)
*Patients contributed multiple events and events were counted in multiple categories.
**Confidence interval

The risk of major bleeds was similar with PRADAXA 150 mg and warfarin across major subgroups defined by baseline characteristics, with the exception of age, where there was a trend towards a higher incidence of major bleeding on PRADAXA (hazard ratio 1.2, 95% CI: 1.0 to 1.4) for patients ≥ 75 years of age.

There was a higher rate of major gastrointestinal bleeds in patients receiving PRADAXA 150 mg than in patients receiving warfarin (1.6% vs. 1.1%, respectively, with a hazard ratio vs. warfarin of 1.5, 95% CI, 1.2 to 1.9), and a higher rate of any gastrointestinal bleeds (6.1% vs. 4.0%, respectively).

Gastrointestinal Adverse Reactions

Patients on PRADAXA 150 mg had an increased incidence of gastrointestinal adverse reactions (35% vs. 24% on warfarin). These were commonly dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) and gastritis-like symptoms (including GERD, esophagitis, erosive gastritis, gastric hemorrhage, hemorrhagic gastritis, hemorrhagic erosive gastritis, and gastrointestinal ulcer).

Hypersensitivity Reactions

In the RE-LY study, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in < 0.1% of patients receiving PRADAXA.

Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

PRADAXA was studied in 4387 patients in 4 pivotal, parallel, randomized, double-blind trials. Three of these trials were active-controlled (warfarin) (RE-COVER, RE-COVER II, and RE-MEDY), and one study (RE-SONATE) was placebo-controlled. The demographic characteristics were similar among the 4 pivotal studies and between the treatment groups within these studies. Approximately 60% of the treated patients were male, with a mean age of 55.1 years. The majority of the patients were white (87.7%), 10.3% were Asian, and 1.9% were black with a mean CrCl of 105.6 mL/min.

Bleeding events for the 4 pivotal studies were classified as major bleeding events if at least one of the following criteria applied: fatal bleeding, symptomatic bleeding in a critical area or organ (intraocular, intracranial, intraspinal or intramuscular with compartment syndrome, retroperitoneal bleeding, intra-articular bleeding, or pericardial bleeding), bleeding causing a fall in hemoglobin level of 2.0 g/dL (1.24 mmol/L or more, or leading to transfusion of 2 or more units of whole blood or red cells).

RE-COVER and RE-COVER II studies compared PRADAXA 150 mg twice daily and warfarin for the treatment of deep vein thrombosis and pulmonary embolism. Patients received 5-10 days of an approved parenteral anticoagulant therapy followed by 6 months, with mean exposure of 164 days, of oral only treatment; warfarin was overlapped with parenteral therapy. Table 3 shows the number of patients experiencing bleeding events in the pooled analysis of RE-COVER and RE-COVER II studies during the full treatment including parenteral and oral only treatment periods after randomization.

Table 3 : Bleeding Events in RE-COVER and RE-COVER II Treated Patients

  Bleeding Events-Full Treatment Period Including Parenteral Treatment
PRADAXA 150 mg twice daily
N (%)
Warfarin
N (%)
Hazard Ratio (95% CI)c
Patients N=2553 N=2554  
Major bleeding eventa 37 (1.4) 51 (2.0) 0.73 ( 0.48, 1.11)
  Fatal bleeding 1 (0.04) 2 (0.1)  
  Bleeding in a critical area or organ 7 (0.3) 15 (0.6)  
  Fall in hemoglobin ≥ 2g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells 32 (1.3) 38 (1.5)  
Bleeding sites for MBEb
  Intracranial 2 (0.1) 5 (0.2)  
  Retroperitoneal 2 (0.1) 1 (0.04)  
  Intraarticular 2 (0.1) 4 (0.2)  
  Intramuscular 2 (0.1) 6 (0.2)  
  Gastrointestinal 15 (0.6) 14(0.5)  
  Urogenital 7 (0.3) 14 (0.5)  
  Other 8 (0.3) 8 (0.3)  
Clinically relevant non-major bleeding 101 (4.0) 170 (6.7) 0.58 (0.46, 0.75)
Any bleeding 411 (16.1) 567 (22.7) 0.70 (0.61, 0.79)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE.
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

The rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg in the full treatment period was 3.1% (2.4% on warfarin).

The RE-MEDY and RE-SONATE studies provided safety information on the use of PRADAXA for the reduction in the risk of recurrence of deep vein thrombosis and pulmonary embolism.

RE-MEDY was an active-controlled study (warfarin) in which 1430 patients received PRADAXA 150 mg twice daily following 6 to 18 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-MEDY study had a combined treatment duration of up to more than 3 years, with mean exposure of 473 days. Table 4 shows the number of patients experiencing bleeding events in the study.

Table 4 : Bleeding Events in RE-MEDY Treated Patients

  PRADAXA 150 mg twice daily
N (%)
Warfarin
N (%)
Hazard Ratio (95% CI)c
Patients N=1430 N=1426  
Major bleeding eventa 13 (0.9) 25 (1.8) 0.54 (0.25, 1.16)
  Fatal bleeding 0 1 (0.1)  
  Bleeding in a critical area or organ 7(0.5) 11 (0.8)  
  Fall in hemoglobin ≥ 2g/dL or transfusion ≥ 2 units of whole blood or packed red blood cells 7(0.5) 16 (1.1)  
Bleeding sites for MBEb
  Intracranial 2 (0.1) 4 (0.3)  
  Intraocular 4 (0.3) 2 (0.1)  
  Retroperitoneal 0 1 (0.1)  
  Intraarticular 0 2 (0.1)  
  Intramuscular 0 4 (0.3)  
  Gastrointestinal 4 (0.3) 8 (0.6)  
  Urogenital 1 (0.1) 1 (0.1)  
  Other 2 (0.1) 4 (0.3)  
Clinically relevant non-major bleeding 71 (5.0) 125 (8.8) 0.56 (0.42, 0.75)
Any bleeding 278 (19.4) 373 (26.2) 0.71 (0.61, 0.83)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE.
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

In the RE-MEDY study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 3.1% (2.2% on warfarin).

RE-SONATE was a placebo-controlled study in which 684 patients received PRADAXA 150 mg twice daily following 3 to 6 months of oral anticoagulant regimen. Patients in the treatment studies who rolled over into the RE-SONATE study had combined treatment duration up to 9 months, with mean exposure of 165 days. Table 5 shows the number of patients experiencing bleeding events in the study.

Table 5 : Bleeding Events in RE-SONATE Treated Patients

  PRADAXA 150 mg twice daily
N (%)
Placebo
N (%)
Hazard Ratio (95% CI)c
Patients N=684 N=659  
Major bleeding eventa 2 (0.3) 0  
  Bleeding in a critical area or organ 2 (0.3) 0  
  Gastrointestinalb 2 (0.3) 0  
Clinically relevant non-major bleeding 34 (5.0) 13 (2.0) 2.54 (1.34, 4.82)
Any bleeding 72 (10.5) 40 (6.1) 1.77 (1.20, 2.61)
Note: MBE can belong to more than one criterion.
aPatients with at least one MBE.
bBleeding site based on investigator assessment. Patients can have more than one site of bleeding.
cConfidence interval

In the RE-SONATE study, the rate of any gastrointestinal bleeds in patients receiving PRADAXA 150 mg was 0.7% (0.3% on placebo).

Clinical Myocardial Infarction Events

In the active-controlled VTE studies, a higher rate of clinical myocardial infarction was reported in patients who received PRADAXA [20 (0.66 per 100 patient-years)] than in those who received warfarin [5 (0.17 per 100 patient-years)]. In the placebo-controlled study, a similar rate of non-fatal and fatal clinical myocardial infarction was reported in patients who received PRADAXA [1 (0.32 per 100 patient-years)] and in those who received placebo [1 (0.34 per 100 patient-years)].

Gastrointestinal Adverse Reactions

In the four pivotal studies, patients on PRADAXA 150 mg had a similar incidence of gastrointestinal adverse reactions (24.7% vs. 22.7% on warfarin). Dyspepsia (including abdominal pain upper, abdominal pain, abdominal discomfort, and epigastric discomfort) occurred in patients on PRADAXA in 7.5% vs. 5.5% on warfarin, and gastritis-like symptoms (including gastritis, GERD, esophagitis, erosive gastritis and gastric hemorrhage) occurred at 3.0% vs. 1.7%, respectively.

Hypersensitivity Reactions

In the 4 pivotal studies, drug hypersensitivity (including urticaria, rash, and pruritus), allergic edema, anaphylactic reaction, and anaphylactic shock were reported in 0.1% of patients receiving PRADAXA.

Postmarketing Experience

The following adverse reactions have been identified during post approval use of PRADAXA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following adverse reactions have been identified during post approval use of PRADAXA: angioedema, thrombocytopenia, esophageal ulcer.

Read the Pradaxa (dabigatran etexilate mesylate) Side Effects Center for a complete guide to possible side effects

DRUG INTERACTIONS

Reduction Of Risk Of Stroke And Systemic Embolism In Non-valvular Atrial Fibrillation

The concomitant use of PRADAXA with P-gp inducers (e.g., rifampin) reduces exposure to dabigatran and should generally be avoided [see CLINICAL PHARMACOLOGY].

P-gp inhibition and impaired renal function are the major independent factors that result in increased exposure to dabigatran [see CLINICAL PHARMACOLOGY]. Concomitant use of P-gp inhibitors in patients with renal impairment is expected to produce increased exposure of dabigatran compared to that seen with either factor alone.

In patients with moderate renal impairment (CrCl 30-50 mL/min), consider reducing the dose of PRADAXA to 75 mg twice daily when administered concomitantly with the P-gp inhibitors dronedarone or systemic ketoconazole. The use of the P-gp inhibitors verapamil, amiodarone, quinidine, clarithromycin, and ticagrelor does not require a dose adjustment of PRADAXA. These results should not be extrapolated to other P-gp inhibitors [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

The concomitant use of PRADAXA and P-gp inhibitors in patients with severe renal impairment (CrCl 15-30 mL/min) should be avoided [see WARNINGS AND PRECAUTIONS, Use In Specific Populations, and CLINICAL PHARMACOLOGY].

Treatment And Reduction In The Risk Of Recurrence Of Deep Venous Thrombosis And Pulmonary Embolism

Avoid use of PRADAXA and P-gp inhibitors in patients with CrCl < 50 mL/min [see WARNINGS AND PRECAUTIONS, Use in Specific Populations, and CLINICAL PHARMACOLOGY].

Read the Pradaxa Drug Interactions Center for a complete guide to possible interactions

Last reviewed on RxList: 8/27/2014
This monograph has been modified to include the generic and brand name in many instances.

Side Effects
Interactions
A A A

Pradaxa - User Reviews

Pradaxa User Reviews

Now you can gain knowledge and insight about a drug treatment with Patient Discussions.

Here is a collection of user reviews for the medication Pradaxa sorted by most helpful. Patient Discussions FAQs

Report Problems to the Food and Drug Administration

 

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.


Women's Health

Find out what women really need.